Aurora Biopharma is founded on a single mission to revolutionize the treatment of cancer, by using the human body’s immune system. Aurora is developing state-of-the-art cancer immunotherapy, a form of adoptive cell transfer called Chimeric Antigen Receptor (CAR) T cells therapy. A cancer patient’s blood is withdrawn, and their T cell is extracted from their white blood cells, genetically edited to express a CAR specific to that type of cancer cell, and re-infused back to the patient to target and kill cancer cells. The US Food & Drug Administration (FDA) has awarded CAR T Cell Therapy its Breakthrough Therapy Designation in the treatment of pediatric and adult acute lymphoblastic leukemia and non-Hodgkin lymphoma.